Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)

被引：0
|
作者：
Kevlicius, Lukas [1 ,2 ]
Smalinskaite, Tautvile [1 ,2 ]
Trociukas, Igoris [1 ]
Pileckyte, Regina [1 ,2 ]
Cekauskiene, Rita [1 ]
Davainis, Linas [1 ]
Daukelaite, Guoda [1 ,2 ]
Vaitekenaite, Vilmante [1 ,2 ]
Strumskyte, Juste [1 ]
Jaramine, Vaida [1 ]
Slobinas, Arturas [1 ]
Jucaitiene, Renata [1 ]
Slepikiene, Inga [1 ]
Bukauskas, Adomas [1 ]
Stoskus, Mindaugas [1 ]
Batiuskaite, Raminta [1 ]
Norvilas, Rimvydas [1 ]
Velceckiene, Vilma [1 ]
Valentine, Egle Gineikiene [1 ]
Dirse, Vaidas [1 ]
Griskevicius, Laimonas [1 ,2 ]
Zucenka, Andrius [1 ]
机构：
[1] Vilnius Univ Hosp Santaros Klin, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania
[2] Inst Clin Med, Dept Hematol & Oncol, Fac Med, Vilnius, Lithuania
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
AML; myelodysplastic syndrome; sequential allogeneic hematopoietic stem cell transplantation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-672
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [1] Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2)
    Vasilevska, Dominika
    Daukelaite, Guoda
    Trociukas, Igoris
    Pileckyte, Regina
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S309 - S309
  • [2] Feasibility and safety of Venetoclax-based bridging to allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) for high-risk Acute Myeloid Leukemia (AML)
    Pabst, C.
    Sauer, T.
    Stadtherr, P.
    Hegenbart, U.
    Luft, T.
    Hundemer, M.
    Schlenk, R. F.
    Mueller-Tidow, C.
    Dreger, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 51 - 51
  • [3] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
    Swaminathan, Mahesh
    Dinardo, Courtney Denton
    Maiti, Abhishek
    Pemmaraju, Naveen
    Ohanian, Maro
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Short, Nicholas James
    Wierda, William G.
    Jain, Nitin
    Kornblau, Steven Mitchell
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Prognostic factors for allogeneic stem cell transplantation (ASCT) for refractory acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS).
    Wong, R
    Shahjahan, M
    De Lima, M
    Anagnostopoulos, A
    Estey, E
    Champlin, R
    Andersson, B
    Khouri, I
    Giralt, S
    BLOOD, 2002, 100 (11) : 853A - 853A
  • [5] Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation
    Andrius Zucenka
    Vilmante Vaitekenaite
    Kazimieras Maneikis
    Linas Davainis
    Regina Pileckyte
    Igoris Trociukas
    Valdas Peceliunas
    Tadas Zvirblis
    Vytautas Staras
    Laimonas Griskevicius
    Bone Marrow Transplantation, 2021, 56 : 2804 - 2812
  • [6] Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation
    Zucenka, Andrius
    Vaitekenaite, Vilmante
    Maneikis, Kazimieras
    Davainis, Linas
    Pileckyte, Regina
    Trociukas, Igoris
    Peceliunas, Valdas
    Zvirblis, Tadas
    Staras, Vytautas
    Griskevicius, Laimonas
    BONE MARROW TRANSPLANTATION, 2021, 56 (11) : 2804 - 2812
  • [7] Decitabine As Induction Therapy For Median-To-High-Risk Myelodysplastic Syndromes(MDS) and Acute Myeloid Leukemia(AML) Before Allogeneic Stem Cell Transplantation
    Zhou, Lin
    Wu Depei
    Fu, Chengcheng
    Sun, Aining
    Qiu, Huiying
    Jin, Zhengming
    Tang, XiaoWen
    Han, Yue
    Ma, Xiao
    He, Guangsheng
    BLOOD, 2013, 122 (21)
  • [8] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and PostHypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Rivera, Daniel
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Faderl, Stefan
    Sasaki, Koji
    Short, Nicholas J.
    Daver, Naval
    Di Nardo, Courtney D.
    Masarova, Lucia
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Borthakur, Gautham
    Al Azzawi, Hind
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop
    Ravandi, Farhad
    Alvarado, Yesid
    BLOOD, 2021, 138
  • [9] Survival of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients Receiving Stem Cell Transplantation (SCT)
    Nath, Rajneesh
    Reddy, Vijay
    Kapur, Anil
    Gebregergish, Samron
    Gurskyte, Laura
    Kulakova, Margarita
    Heeg, Bart
    Berger, Mark S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [10] Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.
    Mukherjee, Akash
    Milton, Denai R.
    Jabbour, Elias
    Konopleva, Marina
    Dinardo, Courtney Denton
    Gulbis, Alison
    Ravandi, Farhad
    Daver, Naval Guastad
    Kadia, Tapan M.
    Oran, Betul
    Popat, Uday R.
    Ciurea, Stefan O.
    Im, Jin
    Kebriaei, Partow
    Mehta, Rohtesh S.
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Khouri, Issa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345